15results about "Somatostatins" patented technology

The present application relates to animals or cells having a myostatin gene with a 12 base pair deletion in the second exon. The application may also include compositions capable of engineering a 12 base pair deletion in the myostatin gene to construct animals or cells. The application also relates to the use of the compositions to increase muscle mass.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

A composition for modifying a myostatin gene, the composition comprising: a guide RNA; a Cas protein; wherein the target sequence is one selected from: SEQ ID NO: 38-60 and the guide sequence is one s

The present invention provides a use of a polypeptide complex on the basis of Titin-Telethonin beta-pleated sheet structure as a polypeptide or protein drug carrier, a method, and a fusion protein complex thereof. The polypeptide complex is capable of maintaining the activity of polypeptide or protein drugs and prolonging the half-life period simultaneously.

The present invention relates generally to the field of bioconjugation. More particularly, the present invention relates to trivalent phosphonates and their use as reducing disulfide heavy bridging agents. Accordingly, the present invention relates to compounds selected from the group consisting of compounds of formula (la) and (lb), conjugates obtained by linking these compounds to another moiety, methods of modifying disulfide containing compounds using compounds selected from the group consisting of compounds of formula (la) and (lb), and compounds obtained by such methods.

The present invention relates to halogenated somatostatin analogs with selectivity for multiple somatostatin receptor subtypes and pharmaceutical compositions comprising the same. Moreover, the present invention relates to said halogenated somatostatin analogs and pharmaceutical compositions for use in therapy and / or diagnosis, for example in the treatment and / or diagnosis of diseases (e.g., cancer such as a neuroendocrine cancer) that are characterized by a high expression (e.g., overexpression) of one or more somatostatin receptor subtypes (e.g., somatostatin receptor 2 (SST2) and / or somatostatin receptor 5 (SST5)).

The invention relates to an adaptor molecule for targeting a cancer cell, comprising a somatostatin receptor 2 (SSTR2) targeting moiety, a linker moiety, and a tag moiety, wherein the SSTR2 targeting moiety is connected to the tag moiety by means of the linker moiety.

Described herein is a dual-functional tetrazine–allyl reagent that enables site-selective disulfide modification in peptides and proteins, serving both as a Michael acceptor for bis-thiols and as a reactive handle for Inverse Electron-Demand Diels–Alder (IEDDA) click chemistry to introduce functional payloads.

The present disclosure relates to methods of large scale synthesis of radionuclide complex solutions having a high activity for diagnostic and / or therapeutic purposes, their use in the commercial production of radioactive drug substances, and to respective solutions as well as containers comprising said solutions.

The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to type 2 somatostatin receptors, compositions thereof and uses thereof in methods of treatment.

The present application relates to an engineered cell, an engineered protomyostatin protein, compositions comprising the same, nucleic acids encoding the same, and methods of production thereof. The engineered cells comprise a myostatin gene that is artificially modified. In some embodiments, the engineered cell expresses less myostatin mRNA as compared to a wild type cell. In addition, the engineered cell can express a mature myostatin protein having the same amino acid sequence as a wild-type animal.

The present invention relates to an extruded depot for sustained release of an active agent comprising at least one active agent and at least one first compound from the class of biodegradable organic polymers based on lactic acid and / or glycolic acid.

SOLUTION: Compositions and methods are disclosed for targeted delivery of therapeutic polypeptides and protein-based therapeutics across the gastrointestinal lining. In one embodiment, provided is a polypeptide construct comprising: (a) a first polypeptide, the first polypeptide comprising an amino acid sequence at least 80% identical to an amino acid sequence selected from any one of SEQ ID NOS: 1-40; and (b) a second polypeptide, the second polypeptide being heterologous to the first polypeptide. In one embodiment, the heterologous polypeptide is a therapeutic polypeptide.

The present invention relates to novel structures, synthesis methods, and applications of human somatostatin analogs comprising either a cyclic or non-cyclic hexapeptide unit, wherein the amino acid residues at positions 2 to 5 are represented by -X1-(D / L)-Trp-X2-X3-, or a cyclic or non-cyclic octapeptide unit, wherein the amino acid residues at positions 2 to 7 are represented by -Cys-X1-(D / L)-Trp-X2-X3-Cys-. In these sequences, X1 is an α-amino acid residue containing an aromatic group on the Cα side chain, X2 is a Lys derivative, and X3 is an α-amino acid residue. The Lys derivative has the following structure: wherein n is 0 or 1; A1, A2, and A3 are independently selected from C(R)2, O, S, NR, C=O, C=S, C=NR, and C=C(R)2. The present invention challenges the conventional understanding that modification of the Lys9 residue in somatostatin significantly reduces biological activity. By altering the Lys9 residue in somatostatin analogs, the present invention provides analogs with enhanced or comparable binding affinity to SSTR2, thereby improving their therapeutic efficacy.